US Patent Issued to Regeneron Pharmaceuticals on April 14 for "Chimeric antigen receptors with MAGE-A4 specificity and uses thereof" (New York Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,793, issued on April 14, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Chimeric antigen receptors with MAGE-A4 specificity and uses thereof" was invented by Kevin Bray (Garnerville, N.Y.), Frank Delfino (Poughquag, N.Y.), David DiLillo (New York) and Thomas Craig Meagher (Yorktown Heights, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "MAGE-A4, or Melanoma-Associated Antigen A4, is a cancer-testis antigen (CTA) on the X chromosome. The present disclosure provides MAGE-A4-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric...